Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Glioblastoma 40Breast Neoplasms 23Gliosarcoma 22Esophageal Neoplasms 21Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 19Pancreatic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Rectal Neoplasms 13Glioma 13Brain Neoplasms 13Uterine Cervical Neoplasms 12Neoplasms 12Lung Neoplasms 11Head and Neck Neoplasms 11Melanoma 10Astrocytoma 10Sarcoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Central Nervous System Neoplasms 8Stomach Neoplasms 7Lymphoma, Follicular 6Esophageal Squamous Cell Carcinoma 6Endometrial Neoplasms 6Adenocarcinoma Of Esophagus 6Oropharyngeal Neoplasms 5Neoplasm Metastasis 5Lymphoma 5Carcinoma 5Burkitt Lymphoma 5

Interventions

Radiotherapy 2Bronchoscopy 2X-Rays 1Taxes 1Radiation 1Paclitaxel 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hemoptysis × Radiation × Clear all
NCT00387374 2013-01-17

Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Hemoptysis, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡